Doximity stock performance sets the stage for closer investor attention

Doximity (DOCS) has seen mixed share performance recently, with a modest 1 day gain of 3.6% alongside negative returns over the past month, past 3 months, year to date, and the past year.

With the share price at $24.01, the recent 3.6% one-day share price gain contrasts with a 90-day share price return of a 40.9% decline and a 1-year total shareholder return of a 57.6% decline, pointing to fading momentum after a weak stretch.

If this kind of move has you reassessing your watchlist, it could be a useful moment to look across healthcare-focused AI platforms and see how other names stack up using 33 healthcare AI stocks

With Doximity trading at $24.01 and data pointing to a sizeable gap to some valuation estimates, the key question is whether the recent share price slide leaves undervalued potential here or whether the market already prices in future growth.

Most Popular Narrative: 36.4% Undervalued

With Doximity last closing at $24.01 and the most followed narrative pointing to a fair value of $37.77, the gap between price and projected value catches the eye.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, which would support long-term revenue and margin expansion.

Curious how a healthcare software platform with steady revenue forecasts still lands at a premium fair value multiple and higher earnings power assumptions? The narrative leans heavily on engagement, margin resilience, and future monetization of clinician tools, but the exact mix of growth, profitability, and valuation inputs might surprise you.

Result: Fair Value of $37.77 (UNDERVALUED)

However, heavy reliance on pharma marketing budgets and the choice to keep key AI tools free for now could both limit revenue momentum and unsettle the current valuation story.

Next Steps

If this mix of optimism and concern leaves you undecided, take a closer look at the numbers now and shape your own view with 4 key rewards

Looking for more investment ideas?

If Doximity has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to spot other opportunities before they move without you.

• Target potential turnaround stories by scanning 25 elite penny stocks with strong financials that combine smaller size with stronger fundamentals than many of their peers.
• Prioritize value by reviewing 56 high quality undervalued stocks that pair solid cash flows with balance sheets built to handle tougher conditions.
• Reduce sleepless nights by focusing on 72 resilient stocks with low risk scores that score well on stability while still offering meaningful upside potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.